Advisory & CMC strategy
Program and CMC roadmaps for mAbs and recombinant proteins, including risk assessment, study design, and USDA 9CFR–aligned experimental planning and reporting.
Biologics CDMO for complex CHO/HEK programs.
ArtProtein partners with emerging and mid-size biotechs to design, express, and develop antibodies and recombinant proteins using stable and transient CHO/HEK platforms.
Our team brings more than 20 years of experience in biologics R&D, process development, CMC documentation, and USDA 9CFR–related studies.
Platforms
CHO / HEK
Expression
Stable & transient
Scope
Advisory & non-GMP
What we do
Expression & process development
Stable and transient CHO/HEK expression, scale-down models through to process-controlled bioreactors, and DoE-driven upstream and purification concepts.
Analytics & regulatory support
Fit-for-purpose development data, CMC summaries, and USDA 9CFR proposal and report support to help you communicate clearly with regulators and partner CDMOs.